Compare Best Buy Co Inc (BBY) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs Becton Dickinson and Co — how do they compare? Best Buy Co Inc trades at $85.41 (market cap $17.70B), while Becton Dickinson and Co trades at $156 (market cap $41.51B). The key difference: Becton Dickinson and Co is far larger — about 2.3× Best Buy Co Inc's market cap, and Best Buy Co Inc pays the higher dividend (4.57%). Which is the better fit depends on your goals.
| BBY | BDX | |
|---|---|---|
Market Cap | $17.70B | $41.51B |
Sector | Consumer Cyclical | Health |
52-Week High | $84.00 | $185.39 |
52-Week Low | $55.52 | $135.49 |
Enterprise Value | $20.08B | $57.97B |
Dividend Yield | 4.57% | 2.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Best Buy (BBY) trades at $81.65, down 1.39% on the day, with a bullish technical outlook and strong recent earnings beats. The stock shows robust profitability with a 39.1% ROE and trades at attractive valuations (P/E 15.12, P/S 0.41). Recent news highlights leadership changes and strategic shifts toward higher-margin businesses like marketplace and retail media, supported by new product launches such as RGB LED TVs and Meta VR partnerships.
The outlook is cautiously optimistic with a consensus price target of $82.17 offering modest upside. Key opportunities include dividend yield near 5% and earnings momentum, while risks involve revenue declines, competitive pressures, and macroeconomic sensitivity. Analyst sentiment is mixed with 34% buy ratings, reflecting balanced views on growth potential versus execution challenges.
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
